Drug Therapy Protocols: Atropine
... Under no circumstances will the QAS, its employees or agents, be liable for any loss, injury, claim, liability or damages of any kind resulting from the unauthorised use of, or reliance upon the CPM or its contents. While effort has been made to contact all copyright owners this has not always been ...
... Under no circumstances will the QAS, its employees or agents, be liable for any loss, injury, claim, liability or damages of any kind resulting from the unauthorised use of, or reliance upon the CPM or its contents. While effort has been made to contact all copyright owners this has not always been ...
GenerAl dIsCussIon
... corrected for BMI (p=0.003). This is the first study to show that the “obesity paradox” also exists in patients with predicted severe pancreatitis. Mortality in obese patients with predicted severe pancreatitis is only higher as compared to non-obese patients when they suffer from central overweight ...
... corrected for BMI (p=0.003). This is the first study to show that the “obesity paradox” also exists in patients with predicted severe pancreatitis. Mortality in obese patients with predicted severe pancreatitis is only higher as compared to non-obese patients when they suffer from central overweight ...
How to manage Correspondence
... parenteral labetalol specifically in a subgroup analysis, hydralazine was a more effective antihypertensive [26]. A subsequently published trial found no between-group difference in persistent severe hypertension (5% in each group) but maternal hypotension occurred in 2/100 women treated with hydral ...
... parenteral labetalol specifically in a subgroup analysis, hydralazine was a more effective antihypertensive [26]. A subsequently published trial found no between-group difference in persistent severe hypertension (5% in each group) but maternal hypotension occurred in 2/100 women treated with hydral ...
IJBCP International Journal of Basic & Clinical
... • Determination of the efficacy and safety of oral fumarate in RRMS (DEFINE) • Comparator and an oral fumarate in RRMS (CONFIRM). Both DEFINE and CONFIRM were 2 years, randomized, placebo-controlled trials, evaluating clinical relapses, progressive disability, and MRI disease activity in a subset ...
... • Determination of the efficacy and safety of oral fumarate in RRMS (DEFINE) • Comparator and an oral fumarate in RRMS (CONFIRM). Both DEFINE and CONFIRM were 2 years, randomized, placebo-controlled trials, evaluating clinical relapses, progressive disability, and MRI disease activity in a subset ...
Shock - Calgary Emergency Medicine
... or against the use of early or larger volume fluid resuscitation in the treatment of uncontrolled haemorrhage. While vigorous fluid resuscitation may be lifesaving in some patients, results from clinical trials are inconclusive.” ...
... or against the use of early or larger volume fluid resuscitation in the treatment of uncontrolled haemorrhage. While vigorous fluid resuscitation may be lifesaving in some patients, results from clinical trials are inconclusive.” ...
14 - Association of Interruptions With an Increased Risk and Severity
... Initial pilot field observations revealed that the drug administration process is not linear. Nurses frequently move between drug preparation and administration as well as among patients during a medication round. For example, a nurse may commence the preparation of an intravenous (IV) drug and prio ...
... Initial pilot field observations revealed that the drug administration process is not linear. Nurses frequently move between drug preparation and administration as well as among patients during a medication round. For example, a nurse may commence the preparation of an intravenous (IV) drug and prio ...
FDA-IND Application Guidance
... vi. CV for all investigators participating in the research vii. Medical License for all investigators participating in the research viii. Laboratory normal values for the lab in use for the research ix. CAP and CLIA certificates for the lab in use for the research x. Letter permitting an IND cross-f ...
... vi. CV for all investigators participating in the research vii. Medical License for all investigators participating in the research viii. Laboratory normal values for the lab in use for the research ix. CAP and CLIA certificates for the lab in use for the research x. Letter permitting an IND cross-f ...
AGIOS PHARMACEUTICALS INC (Form: 8-K
... expectations and beliefs, including the risks and uncertainties relating to: Agios’ ability to successfully commence and complete necessary preclinical and clinical development of its product candidates; Agios’ results of clinical trials and preclinical studies, including subsequent analysis of exis ...
... expectations and beliefs, including the risks and uncertainties relating to: Agios’ ability to successfully commence and complete necessary preclinical and clinical development of its product candidates; Agios’ results of clinical trials and preclinical studies, including subsequent analysis of exis ...
DRUG EVALUATION Drugs 41 (I): 87-103. 1991 00 1 2
... failure. Torasemide was as effective as furosemide in promoting diuresis and preventing weighs gain without adversely affecting neurological status. Finally, the combination of torasemide with spironolactone has been shown to be as effective as furosemide/spironolactone and more effective than spiro ...
... failure. Torasemide was as effective as furosemide in promoting diuresis and preventing weighs gain without adversely affecting neurological status. Finally, the combination of torasemide with spironolactone has been shown to be as effective as furosemide/spironolactone and more effective than spiro ...
Efficacy of atypical v. typical antipsychotics in the treatment of early
... drugs. However, meta-analyses of clinical trials in participants with chronic schizophrenia have suggested a limited advantage of the newer agents in terms of efficacy1–4 and two recent large trials failed to find a difference between these two classes of antipsychotics.5,6 Furthermore, economic ana ...
... drugs. However, meta-analyses of clinical trials in participants with chronic schizophrenia have suggested a limited advantage of the newer agents in terms of efficacy1–4 and two recent large trials failed to find a difference between these two classes of antipsychotics.5,6 Furthermore, economic ana ...
Advances in Lung Cancer 2016: a year in review
... Approved doses of TKIs are: gefitinib 250mg daily, erlotinib 150mg daily (1st generation TKIs); afatinib 40mg daily (2nd generation TKI); osimertinib 80mg daily (3rd generation TKI). #Most common exon 19 deletion is delE746_A750 (LREA motif). *Cause of acquired resistance to gefitinib, erlotinib and ...
... Approved doses of TKIs are: gefitinib 250mg daily, erlotinib 150mg daily (1st generation TKIs); afatinib 40mg daily (2nd generation TKI); osimertinib 80mg daily (3rd generation TKI). #Most common exon 19 deletion is delE746_A750 (LREA motif). *Cause of acquired resistance to gefitinib, erlotinib and ...
summary - Pulmonary Engineering Group Dresden
... Randomization ............................................................................................................................ 19 ...
... Randomization ............................................................................................................................ 19 ...
avodart soft gelatin capsules
... lower than baseline. While mean values for all semen parameters at all time-points remained within the normal ranges and did not meet predefined criteria for a clinically significant change (30%), 2 subjects in the dutasteride group had decreases in sperm count of greater than 90% from baseline at 5 ...
... lower than baseline. While mean values for all semen parameters at all time-points remained within the normal ranges and did not meet predefined criteria for a clinically significant change (30%), 2 subjects in the dutasteride group had decreases in sperm count of greater than 90% from baseline at 5 ...
Cervical Arthroplasty
... The CerviCore disc is currently being investigated in an FDA study. This multicenter, prospective trial compares the CerviCore device with anterior cervical fusion in a 1:1 randomization design. Subjects must have primary singlelevel symptomatic degenerative disc disease that is refractory to nonope ...
... The CerviCore disc is currently being investigated in an FDA study. This multicenter, prospective trial compares the CerviCore device with anterior cervical fusion in a 1:1 randomization design. Subjects must have primary singlelevel symptomatic degenerative disc disease that is refractory to nonope ...
Objectives: 7 A, B, C - College of Southern Idaho
... Development (Section C) and Clinical Experience Tally (Section D) during the evaluation as well. A Satisfactory or Unsatisfactory clinical evaluation is based on demonstration of skills and applied knowledge. Any student receiving an ‘Unsatisfactory’ final clinical evaluation grade at the end of the ...
... Development (Section C) and Clinical Experience Tally (Section D) during the evaluation as well. A Satisfactory or Unsatisfactory clinical evaluation is based on demonstration of skills and applied knowledge. Any student receiving an ‘Unsatisfactory’ final clinical evaluation grade at the end of the ...
Management of Biochemically Recurrent Prostate Cancer After
... intermittent) before physicians and patients can act with confidence. Similar questions about optimal treatment and best timing of treatment arise with other stratification factors, such as time-to-BCR, patient age and comorbidities, Gleason score, and pathologic stage. Therefore, multiple clinical ...
... intermittent) before physicians and patients can act with confidence. Similar questions about optimal treatment and best timing of treatment arise with other stratification factors, such as time-to-BCR, patient age and comorbidities, Gleason score, and pathologic stage. Therefore, multiple clinical ...
Airways Register Search update 2008
... in adults but very few studies have examined it in children. This study therefore investigated the efficacy and safety of this sublingual immunotherapy (SLIT) at the dosage of 1000 AU five times a week without any up-dosing. Forty allergic children (17 M and 23 F, mean age 7 years, range 4-16 years) ...
... in adults but very few studies have examined it in children. This study therefore investigated the efficacy and safety of this sublingual immunotherapy (SLIT) at the dosage of 1000 AU five times a week without any up-dosing. Forty allergic children (17 M and 23 F, mean age 7 years, range 4-16 years) ...
(PSD) March 2015 PBAC meeting
... bioequivalent or therapeutically equivalent, or that justification for not needing bioequivalence or therapeutic equivalence data has been provided to and accepted by the Therapeutic Goods Administration. It would thus be expected that these brands may be interchanged without differences in clinical ...
... bioequivalent or therapeutically equivalent, or that justification for not needing bioequivalence or therapeutic equivalence data has been provided to and accepted by the Therapeutic Goods Administration. It would thus be expected that these brands may be interchanged without differences in clinical ...
Collagenase clostridium histolyticum
... The TGA administers the Therapeutic Goods Act 1989 (the Act), applying a risk management approach designed to ensure therapeutic goods supplied in Australia meet acceptable standards of quality, safety and efficacy (performance), when necessary. ...
... The TGA administers the Therapeutic Goods Act 1989 (the Act), applying a risk management approach designed to ensure therapeutic goods supplied in Australia meet acceptable standards of quality, safety and efficacy (performance), when necessary. ...
Information flow from RDC to ARISg
... Drug Safety queries can be entered on the eSAE case form and also on related forms (i.e., AE, CT Demographics and Baseline Conditions). These queries will be identified as having been entered into RDC by Drug Safety personnel. ...
... Drug Safety queries can be entered on the eSAE case form and also on related forms (i.e., AE, CT Demographics and Baseline Conditions). These queries will be identified as having been entered into RDC by Drug Safety personnel. ...
article - InDex Pharmaceuticals
... that are found in abundance on mucosal surfaces such as the colonic mucosa. Through rectal administration of DIMS0150 in the form of an enema, the agent comes in direct contact with a large number of target cells thereby ensuring a robust immunomodulatory response. Activation of TLR9 by DIMS0150 res ...
... that are found in abundance on mucosal surfaces such as the colonic mucosa. Through rectal administration of DIMS0150 in the form of an enema, the agent comes in direct contact with a large number of target cells thereby ensuring a robust immunomodulatory response. Activation of TLR9 by DIMS0150 res ...
Drug Efficacy Protocol 2008
... falciparum or P. vivax who meet the study inclusion criteria will be enrolled, treated on site with dihydroarteminisinin-piperaquine, and monitored for 42 days for P. falciparum and 28 days for P. vivax. The follow-up will consist of a fixed schedule of check-up visits and corresponding clinical and ...
... falciparum or P. vivax who meet the study inclusion criteria will be enrolled, treated on site with dihydroarteminisinin-piperaquine, and monitored for 42 days for P. falciparum and 28 days for P. vivax. The follow-up will consist of a fixed schedule of check-up visits and corresponding clinical and ...
Developing Cures, Creating Jobs
... the safety and effectiveness of that treatment in patients. Some trials are also conducted to compare existing treatments and some are done to explore whether a drug is appropriate for a different patient population, such as children. Still others are conducted to find ways to make existing approved ...
... the safety and effectiveness of that treatment in patients. Some trials are also conducted to compare existing treatments and some are done to explore whether a drug is appropriate for a different patient population, such as children. Still others are conducted to find ways to make existing approved ...
The role of intra-articular hyaluronan (Sinovial) in the treatment
... joints found in the knees, hands and hips.[1] Treatment options are primarily aimed at relieving the pain stemming from OA, yet many patients do not respond to management strategies involving non-pharmacological interventions, or are not able to tolerate analgesic/anti-inflammatory therapy due to to ...
... joints found in the knees, hands and hips.[1] Treatment options are primarily aimed at relieving the pain stemming from OA, yet many patients do not respond to management strategies involving non-pharmacological interventions, or are not able to tolerate analgesic/anti-inflammatory therapy due to to ...
Transparency and Registration in Clinical Research in the Nordic
... observational studies. Authors of guidelines depend on systematic reviews, from reports on randomised clinical trials, and observational studies. Authors of systematic reviews and overviews depend on randomised clinical trials and observational studies. Randomised clinical trials have a central role ...
... observational studies. Authors of guidelines depend on systematic reviews, from reports on randomised clinical trials, and observational studies. Authors of systematic reviews and overviews depend on randomised clinical trials and observational studies. Randomised clinical trials have a central role ...